HSBC Holdings’s Pyxis Oncology PYXS Stock Holding History

HSBC Holdings’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,358	Closed	-$41.3K	–	3212
2024 Q3	$41.3K	Buy	+11,358	New	+$39.7K	﹤0.01%	2900

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

HSBC Holdings's PYXS Position: Q4 2024 in Review

HSBC Holdings sold out of Pyxis Oncology (PYXS) in Q4 2024, closing a stake of 11,358 shares — an estimated $41.3K sold.

HSBC Holdings first reported a position in PYXS in Q3 2024 and held it in 1 quarter. The position peaked at $41.3K in Q3 2024. 99 funds tracked by Wall St. Rank hold PYXS as of Q4 2024.

HSBC Holdings reported no remaining Pyxis Oncology position as of Q4 2024 after selling out during the quarter.
HSBC Holdings sold 11,358 Pyxis Oncology shares in Q4 2024, an estimated $41.3K.
HSBC Holdings first reported a position in Pyxis Oncology in Q3 2024 and held it in 1 quarter.
HSBC Holdings's Pyxis Oncology position peaked at $41.3K in Q3 2024.
99 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2024.

Based on HSBC Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.